Refine
Has Fulltext
- yes (75)
Is part of the Bibliography
- yes (75)
Year of publication
Document Type
- Journal article (75) (remove)
Keywords
- Biochemie (60)
- Neurospora crassa (4)
- Physiologische Chemie (4)
- bone morphogenetic proteins (2)
- receptor signalling (2)
- ATP carrier (1)
- ATP synthase (1)
- ATPase mutants (1)
- Aminosäuren (1)
- Apoptosis (1)
- B cell receptors (1)
- B cells (1)
- BMP (1)
- BMP antagonist (1)
- Biologie (1)
- Bone morphogenetic protein-2 (1)
- Bone regeneration (1)
- BrdU-Hoechst (1)
- CYR61 (1)
- Cancer (1)
- DNA mediated gene transfer (1)
- Dicyclohexylcarbodiimid (1)
- E. coli atp operon (1)
- Ectopic bone formation (1)
- Escherichia coli (1)
- Escherichia coli-derived recombinant human bone morphogenetic protein-2 (1)
- IL-2 (1)
- IL-4 (1)
- IL-7 (1)
- Interleukin 2 (1)
- Interleukin 4 (1)
- Interleukin 4 (human) (1)
- Interleukin 7 (1)
- Interleukin-4 (1)
- Mechanisms (1)
- Mund-Kiefer-Gesichts-Chirurgie (1)
- Myofibroblast differentiation (1)
- NMR (1)
- NMR spectroscopy (1)
- Oncogene (1)
- Oralchirurgie (1)
- Platelet-derived growthfactor (1)
- Polylactide-co-glycolide (1)
- Proliferation (1)
- R. sphaeroidesl (1)
- Receptor (1)
- Recombinant (1)
- Recombinant DNA (1)
- Smooth-muscle-cells (1)
- Structure-function (1)
- T-Lymphozyt (1)
- T-cells (1)
- TGF-beta (1)
- TGF-β superfamily (1)
- Tumor cell (1)
- amino acid sequence (1)
- antagonist (1)
- automated solid-phase Edman degradation (1)
- b/c1 complex (1)
- bacteriophage lambda (1)
- cDNA (1)
- carbenes (1)
- cartilage induction (1)
- cell binding (1)
- cell cycle (1)
- cell proliferation (1)
- cloning (1)
- conduction de protons (1)
- crystal structure (1)
- cytokines (1)
- drug design (1)
- drug design/partial agonists (1)
- electrostatic potential (1)
- expression plasmid (1)
- flow cytometry (1)
- gene (1)
- gene expression (1)
- growth and differentiation factor 5 (1)
- hematopoietic receptors (1)
- human growth factor (1)
- hybrid-selected translation (1)
- in vitro and in vivo expression (1)
- in vitro expression (1)
- inhibition of H+ translocation (1)
- interleukin 2 (1)
- interleukin 4 (1)
- interleukins (1)
- ligand-receptor complex (1)
- ln vitro mutagenesis (1)
- mRNA and gene (1)
- membrane proteins (1)
- membrane receptor signaling (1)
- mitochondrial ADP (1)
- mitochondrially translated (1)
- molecular recognition (1)
- multiple myeloma (1)
- neutralizing antibodies (1)
- nucleotide sequence (1)
- packaging (1)
- partial agonists (1)
- polycistronic mRNA (1)
- proliferation assays (1)
- protein pathway (1)
- protein structure (1)
- protein-protein recognition (1)
- proteines membranaires (1)
- proteolipid (1)
- proton conduction (1)
- screening (1)
- sequence subunit (1)
- signal transduction (1)
- signaling (1)
- subunit stoichiometry (1)
- translational initiation (1)
- von Willebrand type C domain (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (75) (remove)
Sonstige beteiligte Institutionen
Monoclonal hBMP/NCP (human bone morphogenetic protein anrl associaterl noncollagenous proteins) antiborlies of the lgG class were prorlucerl. In vitro, 12 of 19 hBMP/NCP antiborlies showerl functional inhibition of hBMP/ NCP-induced chondroneogenesis in a neonatal muscle tissue assay. Inducing factors were characterized by their inhibiting antibodies with immunoblotting. Several peptide factors seem to be involved in the cascade of inducerl chondro- and osteogenesis.
Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement
(1992)
lnterleukin-4 (IL-4) represents a prototypic lymphokine (for a recent review see Paul, 1991). It promotes differentiation of B-cells and the proliferation of T- and B-cell, and other cell types of the lymphoid system. An antagonist of human IL-4 was discovered during the studies presented here after Tyr124 of the recombinant proteinbad been substituted by an aspartic acid residue. This IL-4 variant, Y124D, bound with high affinity to the IL-4 receptor (K\(_D\) = 310 pM), but retained no detectable proliferative activity for T -<:ells and inhibited IL-4-dependent T -cell proliferation competitively (K\(_i\) = 620 pM). The loss of efficacy in variant Y124D was estimated to be > 100-fold on the basis of a weak partial agonist activity for the very sensitive induction of CD23 positive B-cells. The subsitution of Tyr124 by either phenylalanine, histidine, asparagine, Iysine or glycine resulted in partial agonist variants with unaltered receptor binding atTmity and relatively small deficiencies in efficacy. These results demoostrate that high affinity binding and signal generation can be uncoupled efticiently in a Iigand of a receptor betonging to the recently identified hematopoietin receptor family. In addition we show for the first time, that a powerful antagonist acting on the IL-4 receptor system can be derived from the IL-4 protein.
Interleukin 4 (IL-4) exerts a decisive role in the coord.ination of proteelive immune responses against parasites, particularly helminths. A disregulation of ll.r4 function is possibly involved in the genesis of allergic disease states. The search for important amino acid residues in human ll.r4 by mutational analysis of charged invariant amino acid positions identified two distinct functional sites in the 4-helix-bundle protein. Site 1 was marked by amino acid substitutions of the glutamic acid at position 9 in helix A and arginine at position 88 in helix C. Exchanges at both positions led to IL-4 variants deficient in binding to the extracellular domain of the ll.r4 receptor (IL-4ReJ. In parallel, up to 1000-fold increased concentrations of this type of variant were required to induce T -cell proliferation and B-eeil CD23 expression. Site 2 was marked by amino acid exchanges in helix D at positions 121, 124 and 125 (arginine, tyrosine and serine respectively in the wild-type).ß.A variants affected at site 2 exhibited partial agonist activity during T -cell proliferation; however, they still bound with high affinity to IL-4Rex. [The generation of an IL-4 antagonist by replacing tyrosine 124 with aspartic acid has been described before by Kruse et al. (1992) (EMBO }., 11, 3237-3244)]. These findings indicate that IL-4 functions by bind.ing IL-4Rex via site 1 which is constituted by residues on helices A and C. They further suggest that the association of a second, still undetined receptor protein with site 2 in helix D activates the receptor system and generates a transmembrane signal.
Mutant proteins (muteins) of human lnterleukin-4 (llA) were constructed by means of in vitro mutagenesis. The muteins were expressed in E. co/1, submitted to a renaturation and purification protocol and analysed for biological activity. Exchange of the cysteines at either position 46 or 99 which form one of the three disulfide bridges resulted. in a nearly co•mplete loss · of biological actiyity and an unstable protein. The exchange of tyrosine 124 also inactivated the protein, while a mutation of tyrosine 56 left some residual activity. Exchange of the other four cysteines or of · the single tryptophane had smaller etTects.
Background
Bone morphogenetic protein (BMP)-2 and growth and differentiation factor (GDF)-5 are two related transforming growth factor (TGF)-β family members with important functions in embryonic development and tissue homeostasis. BMP-2 is best known for its osteoinductive properties whereas GDF-5—as evident from its alternative name, cartilage derived morphogenetic protein 1—plays an important role in the formation of cartilage. In spite of these differences both factors signal by binding to the same subset of BMP receptors, raising the question how these different functionalities are generated. The largest difference in receptor binding is observed in the interaction with the type I receptor BMPR-IA. GDF-5, in contrast to BMP-2, shows preferential binding to the isoform BMPR-IB, which is abrogated by a single amino acid (A57R) substitution. The resulting variant, GDF-5 R57A, represents a “BMP-2 mimic” with respect to BMP receptor binding. In this study we thus wanted to analyze whether the two growth factors can induce distinct signals via an identically composed receptor.
Results
Unexpectedly and dependent on the cellular context, GDF-5 R57A showed clear differences in its activity compared to BMP-2. In ATDC-5 cells, both ligands induced alkaline phosphatase (ALP) expression with similar potency. But in C2C12 cells, the BMP-2 mimic GDF-5 R57A (and also wild-type GDF-5) clearly antagonized BMP-2-mediated ALP expression, despite signaling in both cell lines occurring solely via BMPR-IA. The BMP-2- antagonizing properties of GDF-5 and GDF-5 R57A could also be observed in vivo when implanting BMP-2 and either one of the two GDF-5 ligands simultaneously at heterotopic sites.
Conclusions
Although comparison of the crystal structures of the GDF-5 R57A:BMPR-IAEC- and BMP-2:BMPR-IAEC complex revealed small ligand-specific differences, these cannot account for the different signaling characteristics because the complexes seem identical in both differently reacting cell lines. We thus predict an additional component, most likely a not yet identified GDF-5-specific co-receptor, which alters the output of the signaling complexes. Hence the presence or absence of this component then switches GDF-5′s signaling capabilities to act either similar to BMP-2 or as a BMP-2 antagonist. These findings might shed new light on the role of GDF-5, e.g., in cartilage maintenance and/or limb development in that it might act as an inhibitor of signaling events initiated by other BMPs.
Soluble mitochondrial ATPase (F1) isolated from Neurospora crassa is resolved by dodecylsulfate- gel electrophoresis into five polypeptide bands with apparent molecular weights of 59000, 55000, 36000, 15000 and 12000. At least nine further polypeptides remain associated with ATPase after disintegration of mitochondria with Triton X-100 as shown by the analysis of an immunoprecipitate obtained with antiserum to F 1 A TPase. Two of the associated polypeptides with apparent molecular weights of 19000 and 11000 are translated on mitochondrial ribosomes, as demonstrated by incorporation in vivo of radioactive leueine in the presence of specific inhibitors of mitochondrial (chloramphenicol) and extramitochondrial ( cycloheximide) protein synthesis. The appearance of mitochondrial translation products in the immunoprecipitated A TPase complex is inhibited by' cycloheximide. The same applies for some of the extramitochondrial translation products in the presence of chloramphenicol. This suggests that both types of polypeptides are necessary for the assembly of the A TPase complex.
no abstract available
The structure of the F0 part of ATP synthases from E. coli and Neurospora crassa was analyzed by hydrophobic surface labeling with [125I]TID. In the E. co/i F0 all three subunits were freely accessible to the reagent, suggesting that these subunits are independently integrated in the membrane. Labeted amino acid residues were identified by Edman degradation of the dicyclohexylcarbodiimide binding (DCCD) proteins from E. coli and Neurospora crassa. The very similar patterns obtained with the two homologaus proteins suggested the existence of tightly packed cx-helices. The oligomeric structure of the DCCD binding protein appeared to be very rigid since little, if any, change in the labeling patternwas observed upon addition of oligomycin or DCCD to membranes from Neurospora crassa. When membrancs were pretrcated with DCCD prior to the reaction with [125I]TID an additionally labeled amino acid appeared at the position of Glu·65 which binds DCCD covalently, indicating the Jocation of this inhibitor on the outside of the oligomer. It is suggested that proton conduction occurs at the surface of the oligomer of the DCCD binding protein. Possibly this oligomer rotates against the subunit a or b and thus enables proton translocation. Conserved residues in subunit a, probably located in the Iipid bilayer, might participate in the pro· ton translocation mechanism.